Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting

Inclusion Criteria: * Male or female, age ≥ 18 yrs and \<70 yrs with histologically or cytologically confirmed * Malignant disease * Naive or nonnaive to chemotherapy, with a Karnofsky score of ≥ 60 * Scheduled to receive two courses of moderately emetogenic chemotherapy or cisplatin 60 \~ 80 mg/m2 on study Day 1 * Use of reliable contraceptive measures (for females of childbearing potential) and negative pregnancy test at baseline visit * Patients with hepatic, renal, or cardiovascular impairment eligible at the investigator's discretion * Patients experiencing, at maximum, mild nausea after previous chemotherapy eligible at the investigator's discretion * Predicted life expectancy of ≥ 3 months * Provision of written informed consent. Exclusion Criteria: * Inability to understand or cooperate with study procedures * Receipt of investigational drugs ≤ 30 days before study entry * Receipt of other investigational drugs during the course of this study * Seizure disorder or any condition requiring anticonvulsants, sedatives * CNS malignancy or metastasis * Ongoing emesis due to obstruction of digestive tract * Emesis, retching, or Grade 2 or 3 nausea 24 hrs before chemotherapy * Moderate or severe nausea and vomiting after any previous chemotherapy * Scheduled receipt of any chemotherapeutic agent with an emetogenicity level \>3 during study Days 2-5 * Scheduled receipt of radiotherapy of the upper abdomen or cranium on study Days 2-5 * Scheduled to receive any other drug with potential antiemetic efficacy within 24 h of study initiation and throughout day 5 * Contraindications to 5-HT3 receptor antagonists * Contraindications to chemotherapy